An observational study in Anxiety Disorders, sponsored by Dr Benoit Bataille. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Dr Benoit Bataille · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 309 studies in Anxiety Disorders with a site in France — 74 open to participants now, 78 under way, 1 of them phase 3. Anxiety Disorders · France.
Among the 309 studies in Anxiety Disorders with a site in France, this one is the 30th largest by enrollment of the 105 observational ones that give a count, is one of 16 that started in 2024, is one of 105 observational ones, and was the 261st registered.
7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.
Browse Anxiety Disorders studies →74 of the 309 studies in Anxiety Disorders with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier de Saint-Brieuc · Sites in France
Ages 18+
University Hospital, Grenoble · Sites in France
Ages 18+
Hospital St. Joseph, Marseille, France · Sites in France
Ages 70–100
University Hospital, Clermont-Ferrand · Sites in France
Ages 6–15
University Hospital, Rouen · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 947 Anxiety Disorders studies recruiting now, 423 (45%) set no upper age limit and 455 (48%) stop at 75 or younger; 233 take children under 18; 319 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
309 studies; the count open now beside each. This study's row is marked.
First in 1983; this study’s year is marked. 16 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 466 is above the median of 168 across 979 observational studies indexed under Anxiety Disorders.
Median enrollment 89 across the 204 interventional studies, 150 across the 105 observational. Of the 200 that completed or were terminated, 3 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 309 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Dr Benoit Bataille as lead sponsor.
Dr Benoit Bataille has 1 study filed under Anxiety Disorders — fewer than ten, so there is no comparison to draw.
29 of the studies in Anxiety Disorders with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05681572Phase 3University Hospital, MontpellierEffect of Sedative and Anxiolytic Premedication on Children Experience After General Anesthesia | 2027-10-18 |
| NCT04513444Institut Claudius RegaudInterest of Medical Hypnosis in Anxious Patients Treated by Radiotherapy | 2026-11 |
| NCT07668050University Hospital, Clermont-FerrandA Study of the Impact of a Virtual Reality Medical Device (HypnoVR® Headset) on Anxiety and Pain in Interventional Radiology. | 2026-12 |
| NCT06512662Clinique Pasteur LanrozeSupport Pathway for ENT Cancer Patients in a Support Care Day Hospital | 2026-12-31 |
| NCT05074901University of BordeauxVirtual Agents-based Digital Interventions to Improve Health | 2026-12-31 |
Add all 29 to your calendar (.ics) → With an account.
Among the 309 studies in Anxiety Disorders with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational study aims to assess the potential relationship between tongue colorimetry (using standardized photographic techniques) and anxiety-depression scores measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) in acupuncture patients. Data will be analyzed using machine learning methods to determine whether tongue color features correlate with MADRS scores, possibly contributing to a novel, non-invasive diagnostic tool for anxiety and depression assessment in clinical practice.
Participation involves only tongue photography and completion of questionnaires, without any invasive procedures or treatment modifications.
This prospective observational study investigates the correlation between lingual colorimetry, captured using readily available and standardized modern photographic tools (iPhone cameras), and anxiety-depression scores evaluated by the Montgomery-Åsberg Depression Rating Scale (MADRS) among patients attending routine acupuncture consultations.
Participants will undergo a simple and non-invasive photographic recording of their tongue using an iPhone, ensuring consistent lighting and standardized positioning to minimize variability. Simultaneously, participants will complete the MADRS questionnaire, a widely validated instrument for assessing anxiety and depression severity. No invasive procedures or therapeutic interventions beyond their usual acupuncture care will be performed.
The acquired photographic data will be analyzed using machine learning algorithms to identify potential predictive relationships between distinct colorimetric characteristics of the tongue and the MADRS scores. The objective is to determine whether lingual imaging could serve as a reliable, non-invasive biomarker or complementary diagnostic tool for assessing psychological status in clinical practice.
This approach leverages everyday technology (smartphones), promoting ease of replication and broader accessibility in clinical environments. Ultimately, findings from this study could facilitate early detection and monitoring of anxiety-depressive disorders, thus enhancing individualized patient care in complementary and integrative medicine.
This is a prospective observational monocentric study conducted in an acupuncture practice. The study aims to establish a correlation between tongue colorimetric features and MADRS scores in patients consulting for symptoms related to anxiety.
Tongue photography and MADRS assessment present no risk to participants. A non-opposition declaration for photography and consent for anonymous and confidential data analysis will be obtained.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Correlation using Machine Learning between Tongue Colorimetric Features and MADRS Scores
This study aims to evaluate the correlation between standardized tongue colorimetric parameters (obtained through digital photographs) and depression/anxiety scores measured by the Montgomery-Åsberg Depression Rating Scale (MADRS). Machine learning methods will be used to analyze tongue images and identify potential associations between colorimetric features and MADRS scores. Participants will be categorized into two subgroups: MADRS \< 15 and MADRS ≥ 15, to assess the ability of tongue characteristics to differentiate depression severity.
Time frame: Baseline (single evaluation at enrollment)
Machine Learning Analysis of Tongue Features and MADRS Scores
* Density Diagram. * Partial Correlation Analysis (Train/Test Split): Relationship between tongue color and MADRS scores. * Logistic Regression Model (Train/Test) * Support Vector Machine (SVM) on PCA: Model performance evaluation with ROC analysis. * Deep Learning Model: CNN applied to tongue images, classification based on color and texture. * Shapley Values Interpretation: Feature importance analysis for AI models. * Correlation Between Individual MADRS Items and Tongue Zones: Zone-by-zone statistical analysis. * MANCOVA Analysis: Multivariate analysis of covariance to assess multiple dependent variables. * CNN-based Model on Images: Direct classification of tongue features using convolutional neural networks. * Subgroup Identification via PCA (3 Components): Exploring potential depression subtypes.
Time frame: Baseline (single evaluation at enrollment)
Plan to share: Undecided — The potential sharing of IPD is currently undecided due to ethical considerations regarding the anonymization of tongue photographs. The ethics committee has highlighted the importance of ensuring that no identifiable characteristics can be traced back to participants. If a sharing plan is implemented, it will ensure strict anonymization protocols, including removing metadata, blurring any identifiable features, and restricting access to approved researchers under a confidentiality agreement.
No publications or documents are linked to this record.
Ran from Jun 2024 to primary completion in Nov 2025, 16 months.
Of 413 non-industry observational studies under Anxiety Disorders, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 49. This study's 16 months is below that.
Counting every sponsor, half of 441 studies reached it within 19 months; a quarter within 6 and three quarters within 48.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Dec 2025 → Nov 2025 and completion Jun 2026 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.